109 related articles for article (PubMed ID: 22188924)
1. Characterization of the substituted N-triazole oxindole TROX-1, a small-molecule, state-dependent inhibitor of Ca(V)2 calcium channels.
Swensen AM; Herrington J; Bugianesi RM; Dai G; Haedo RJ; Ratliff KS; Smith MM; Warren VA; Arneric SP; Eduljee C; Parker D; Snutch TP; Hoyt SB; London C; Duffy JL; Kaczorowski GJ; McManus OB
Mol Pharmacol; 2012 Mar; 81(3):488-97. PubMed ID: 22188924
[TBL] [Abstract][Full Text] [Related]
2. Analgesic effects of a substituted N-triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker.
Abbadie C; McManus OB; Sun SY; Bugianesi RM; Dai G; Haedo RJ; Herrington JB; Kaczorowski GJ; Smith MM; Swensen AM; Warren VA; Williams B; Arneric SP; Eduljee C; Snutch TP; Tringham EW; Jochnowitz N; Liang A; Euan MacIntyre D; McGowan E; Mistry S; White VV; Hoyt SB; London C; Lyons KA; Bunting PB; Volksdorf S; Duffy JL
J Pharmacol Exp Ther; 2010 Aug; 334(2):545-55. PubMed ID: 20439438
[TBL] [Abstract][Full Text] [Related]
3. Electrophysiological characterization of activation state-dependent Ca(v)2 channel antagonist TROX-1 in spinal nerve injured rats.
Patel R; Rutten K; Valdor M; Schiene K; Wigge S; Schunk S; Damann N; Christoph T; Dickenson AH
Neuroscience; 2015 Jun; 297():47-57. PubMed ID: 25839150
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the triazine, T4, a representative from a novel series of CaV2 inhibitors with strong state-dependence, poor use-dependence, and distinctively fast kinetics.
Swensen AM; Niforatos W; Lee CH; Jarvis MF; McGaraughty S
Eur J Pharmacol; 2014 Dec; 745():234-42. PubMed ID: 25446431
[TBL] [Abstract][Full Text] [Related]
5. An automated electrophysiological assay for differentiating Ca(v)2.2 inhibitors based on state dependence and kinetics.
Swensen AM; Niforatos W; Vortherms TA; Perner RJ; Li T; Schrimpf MR; Scott VE; Lee L; Jarvis MF; McGaraughty S
Assay Drug Dev Technol; 2012 Dec; 10(6):542-50. PubMed ID: 22428804
[TBL] [Abstract][Full Text] [Related]
6. A high-throughput assay for evaluating state dependence and subtype selectivity of Cav2 calcium channel inhibitors.
Dai G; Haedo RJ; Warren VA; Ratliff KS; Bugianesi RM; Rush A; Williams ME; Herrington J; Smith MM; McManus OB; Swensen AM
Assay Drug Dev Technol; 2008 Apr; 6(2):195-212. PubMed ID: 18471074
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of recombinant N-type calcium channel (Cav2.2) mediated calcium mobilization using FLIPR.
Benjamin ER; Pruthi F; Olanrewaju S; Shan S; Hanway D; Liu X; Cerne R; Lavery D; Valenzano KJ; Woodward RM; Ilyin VI
Biochem Pharmacol; 2006 Sep; 72(6):770-82. PubMed ID: 16844100
[TBL] [Abstract][Full Text] [Related]
8. In vitro characterization of T-type calcium channel antagonist TTA-A2 and in vivo effects on arousal in mice.
Kraus RL; Li Y; Gregan Y; Gotter AL; Uebele VN; Fox SV; Doran SM; Barrow JC; Yang ZQ; Reger TS; Koblan KS; Renger JJ
J Pharmacol Exp Ther; 2010 Nov; 335(2):409-17. PubMed ID: 20682849
[TBL] [Abstract][Full Text] [Related]
9. Kinetics and Gbetagamma modulation of Ca(v)2.2 channels with different auxiliary beta subunits.
Meir A; Dolphin AC
Pflugers Arch; 2002 May; 444(1-2):263-75. PubMed ID: 11976940
[TBL] [Abstract][Full Text] [Related]
10. Effect of mibefradil on voltage-dependent gating and kinetics of T-type Ca(2+) channels in cortisol-secreting cells.
Gomora JC; Xu L; Enyeart JA; Enyeart JJ
J Pharmacol Exp Ther; 2000 Jan; 292(1):96-103. PubMed ID: 10604935
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of recombinant Ca(v)3.1 (alpha(1G)) T-type calcium channels by the antipsychotic drug clozapine.
Choi KH; Rhim H
Eur J Pharmacol; 2010 Jan; 626(2-3):123-30. PubMed ID: 19782679
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of high voltage-activated calcium channels by spider toxin PnTx3-6.
Vieira LB; Kushmerick C; Hildebrand ME; Garcia E; Stea A; Cordeiro MN; Richardson M; Gomez MV; Snutch TP
J Pharmacol Exp Ther; 2005 Sep; 314(3):1370-7. PubMed ID: 15933156
[TBL] [Abstract][Full Text] [Related]
13. State-dependent inhibition of L-type calcium channels: cell-based assay in high-throughput format.
Xia M; Imredy JP; Koblan KS; Bennett P; Connolly TM
Anal Biochem; 2004 Apr; 327(1):74-81. PubMed ID: 15033513
[TBL] [Abstract][Full Text] [Related]
14. Effects of raloxifene on voltage-dependent T-type Ca2+ channels in mouse spermatogenic cells.
Wang Q; Lu L; Gao X; Wang C; Wang J; Cheng J; Gao R; Xiao H
Pharmacology; 2011; 87(1-2):70-80. PubMed ID: 21228613
[TBL] [Abstract][Full Text] [Related]
15. omega-conotoxin GVIA alters gating charge movement of N-type (CaV2.2) calcium channels.
Yarotskyy V; Elmslie KS
J Neurophysiol; 2009 Jan; 101(1):332-40. PubMed ID: 18971294
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the cardiac L-type calcium channel current by the TRPM8 agonist, (-)-menthol.
Baylie RL; Cheng H; Langton PD; James AF
J Physiol Pharmacol; 2010 Oct; 61(5):543-50. PubMed ID: 21081797
[TBL] [Abstract][Full Text] [Related]
17. Use-dependent blockade of Cav2.2 voltage-gated calcium channels for neuropathic pain.
Winquist RJ; Pan JQ; Gribkoff VK
Biochem Pharmacol; 2005 Aug; 70(4):489-99. PubMed ID: 15950195
[TBL] [Abstract][Full Text] [Related]
18. CSTX-1, a toxin from the venom of the hunting spider Cupiennius salei, is a selective blocker of L-type calcium channels in mammalian neurons.
Kubista H; Mafra RA; Chong Y; Nicholson GM; Beirão PS; Cruz JS; Boehm S; Nentwig W; Kuhn-Nentwig L
Neuropharmacology; 2007 Jun; 52(8):1650-62. PubMed ID: 17517422
[TBL] [Abstract][Full Text] [Related]
19. Block of human CaV3 channels by the diuretic amiloride.
Lopez-Charcas O; Rivera M; Gomora JC
Mol Pharmacol; 2012 Oct; 82(4):658-67. PubMed ID: 22767612
[TBL] [Abstract][Full Text] [Related]
20. The inhibitory effect of Ca2+-activated K+ channel activator, BMS on L-type Ca2+ channels in rat ventricular myocytes.
Son YK; Choi SW; Jung WK; Jo SH; Jung ID; Park YM; Choi IW; Sin JI; Shim EB; Kim N; Han J; Park WS
Life Sci; 2011 Aug; 89(9-10):331-6. PubMed ID: 21763323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
